The Belmont Report & Research Ethics: What Every CRC Needs to Know

The Belmont Report is not a historical document you read once and file away. It is the ethical foundation beneath every protocol you work on, every consent form you review, every IRB approval you track, and every decision about whose burden it is to participate in research. Published in 1979 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, it identified three principles, respect for persons, beneficence, and justice, that remain the cornerstone of research ethics in the United States and the basis for all federal human subjects regulations.

For CRCs preparing for certification exams, these principles appear repeatedly. For CRCs working daily in clinical research, they explain why the regulatory framework is built the way it is. This guide covers the Belmont Report in full: its origins, its three principles in depth, and how each one maps to the work you do every day.

Why the Belmont Report Matters to CRCs

The HHS Office for Human Research Protections (OHRP) describes the Belmont Report as continuing to serve as an essential reference for Institutional Review Boards that review research proposals, ensuring that research meets the ethical foundations of federal regulations. It is not a regulation itself: it is the ethical framework from which regulations were built.

Understanding the Belmont Report changes how you engage with compliance requirements. Informed consent is not a form: it is the expression of the principle of respect for persons. IRB review is not a bureaucratic hurdle: it is the institutional mechanism for assessing beneficence and protecting participants from unreasonable risk. Fair selection of research subjects is not a demographic checkbox: it is the application of justice. When you understand why each requirement exists, you become better at identifying when the spirit of a requirement is being met and when it is only being technically satisfied.

Origins: What Made the Belmont Report Necessary

The Belmont Report did not emerge from abstract philosophical debate. It emerged from documented, systematic abuses of human beings in the name of science — abuses that took place not in the distant past or in other countries, but in the United States, within living memory of its publication. HHS's own explanation of why research regulations exist describes the direct chain: documented cases of unethical research prompted public outcry, which led Congress to pass laws requiring federal protections for research participants.

The full text of the Belmont Report, available on HHS.gov, acknowledges this history directly. It notes that public attention was drawn to ethical questions in research by reported abuses of human subjects, especially during the Second World War. The exploitation of prisoners in Nazi concentration camps was condemned as a particularly flagrant injustice. The Nuremberg Code, drafted in response to the Nazi Doctors Trial, became the prototype for later codes intended to ensure ethical conduct in research involving human subjects. The World Medical Association's Declaration of Helsinki, first adopted in 1964, extended these principles specifically to the medical research community.

The Nuremberg Code: The Prototype

The Nuremberg Code, which the Belmont Report cites directly as the prototype for later ethical codes in human research, emerged from the 1946–1947 Nuremberg Medical Trial, the prosecution of 23 Nazi physicians and scientists for conducting lethal experiments on concentration camp prisoners. The Nuremberg Code, published by the HHS Office of Research Integrity, established ten principles governing human experimentation, the first and most foundational of which states that the voluntary consent of the human subject is absolutely essential. It further requires that consent be given by a person with legal capacity to consent, exercised freely, without intervention of any element of force, fraud, deceit, duress, or coercion, and with sufficient understanding of the experiment to make an enlightened decision.

The Code also established several principles that flow directly into modern GCP requirements: that the experiment be based on prior animal experimentation; that unnecessary physical and mental suffering be avoided; that no experiment be conducted where there is reason to believe death or disabling injury will occur; that the humanitarian importance of the objective be proportionate to the risk; and that the human subject be free to end their participation at any time. The HHS Office of Research Integrity documents the direct line from the Nuremberg Code through the Declaration of Helsinki to the Belmont Report and finally to the federal regulations that govern research today. The voluntary consent requirement, placed first in the Code, is the precursor to everything that modern informed consent doctrine requires.

But the proximate cause of the Belmont Report, the event that made its creation politically and morally unavoidable — was American, not German.

The Tuskegee Study: The Event That Changed Research Ethics

In 1932, the U.S. Public Health Service, working with the Tuskegee Institute, began a study of untreated syphilis involving 600 Black men — 399 with syphilis and 201 without the disease. According to the CDC's official account of the study, participants' informed consent was not collected. Researchers told the men they were being treated for "bad blood", a local term covering several ailments, while withholding from them both their actual diagnosis and, critically, their treatment.

The study continued for 40 years. Through the 1950s and 1960s, well after penicillin had been established as an effective cure for syphilis, the men were not offered treatment. As the HHS Office of Research Integrity documents, treatment was withheld specifically so researchers could continue tracking the untreated course of the disease. The study ended in 1972, following widespread media coverage and a Senate investigation. In 1997, President Clinton issued a formal Presidential Apology. A $10 million out-of-court settlement had been reached in 1974; the Tuskegee Health Benefit Program provided medical care to survivors, their wives, widows, and children for decades afterward.

The Tuskegee study's legacy extends far beyond its immediate harm. Research on the lasting effects of this history has documented that it contributed to persistent distrust of medical and research institutions among Black Americans, a distrust with direct consequences for health outcomes and research participation rates that persist decades later. The Belmont Report's explicit acknowledgment of this history in its discussion of justice is not incidental. The selection of disadvantaged, rural Black men to study a disease not confined to that population, while the benefits of the research accrued to the broader population — was precisely the injustice the principle of justice was designed to prevent.

Creating the Belmont Report: The National Commission

The National Research Act of 1974 created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Commission was charged with two tasks: identifying the basic ethical principles that should underlie the conduct of biomedical and behavioral research involving human subjects, and developing guidelines to ensure that such research is conducted in accordance with those principles.

As the HHS Belmont 25th Anniversary materials describe, the Commission met for nearly four years. Its work culminated in an intensive four-day period of deliberations in February 1976 at the Smithsonian Institution's Belmont Conference Center, which gave the report its name. The Commission submitted its final report to the Secretary of HHS in 1978. It was published in the Federal Register in April 1979.

The three principles the Commission identified were not invented from scratch. As the full text of the Belmont Report explains, they were drawn from principles generally accepted in the broader cultural and ethical tradition, selected because they were particularly relevant to the ethics of research involving human subjects and comprehensive enough to guide the resolution of ethical problems arising from that research.

Principle One: Respect for Persons

The Belmont Report describes respect for persons as incorporating two ethical convictions: first, that individuals should be treated as autonomous agents, and second, that persons with diminished autonomy are entitled to protection. An autonomous person is defined as one capable of deliberation about personal goals and of acting under the direction of such deliberation.

The practical application of respect for persons in research is informed consent. The Belmont Report is explicit: respect for persons requires that subjects, to the degree they are capable, be given the opportunity to choose what shall or shall not happen to them. This opportunity is provided when adequate standards for informed consent are satisfied. Three elements are essential to a valid informed consent process: information (participants must receive sufficient information to make a decision), comprehension (that information must be actually understood, not merely presented), and voluntariness (the decision must be free from coercion or undue influence).

The second dimension of respect for persons, protection of those with diminished autonomy, explains the additional regulatory protections for vulnerable populations in research: children, prisoners, people with cognitive impairments, pregnant women. These populations are not excluded from research; they are given heightened protections because their capacity to make fully autonomous decisions may be limited by their circumstances. The federal regulations at 45 CFR Part 46, subparts B, C, and D, exist specifically to operationalize this dimension of the principle for each vulnerable group.

For CRCs, respect for persons governs every interaction with participants from recruitment through study closure. It is why consent must be an ongoing process rather than a one-time signature. It is why participants can withdraw at any time without penalty — coercion through fear of losing benefits is a violation of voluntariness. It is why re-consent is required when a protocol amendment materially affects the risks or procedures a participant faces. None of these requirements are arbitrary bureaucratic steps. Each one is the direct expression of a principle that emerged from documented failures to respect the people who participated in research.

Principle Two: Beneficence

The Belmont Report frames beneficence as an obligation, not merely a virtue, but a duty. Two general rules are identified as complementary expressions of beneficent actions: do not harm, and maximize possible benefits while minimizing possible harms.

The practical application of beneficence is risk/benefit assessment. The Belmont Report identifies this as the most difficult task in research ethics: determining when it is justifiable to seek certain benefits despite the risks involved. The assessment must consider the nature and scope of risks, the probability that harm will occur, the benefits to participants and to society, whether risks are minimized to the extent possible, and whether the research design is sound enough to actually produce the knowledge it seeks.

For CRCs, beneficence is expressed in several daily practices. Adverse event reporting is not just a regulatory requirement: it is the mechanism by which ongoing risk assessment happens in real time. When an unexpected adverse event occurs, the IRB and sponsor must be notified so they can reassess whether the study's risk/benefit balance has shifted. A CRC who delays or omits adverse event reporting is not just violating GCP. They are undermining the live beneficence assessment that protects every participant in the study. Similarly, protocol deviations matter because they introduce variability that may compromise data quality, and data of insufficient quality cannot produce valid evidence, making the risk participants accepted worthless from a beneficence standpoint.

The ICH E6(R3) GCP guideline reflects this principle throughout its emphasis on quality by design, the idea that quality must be designed into a trial's structure from the outset, not inspected in at the end. This is beneficence expressed as a quality management philosophy: research that produces unreliable data does not justify the risks participants accepted.

Principle Three: Justice

The Belmont Report frames justice as a question of fairness in distribution: who ought to receive the benefits of research, and who ought to bear its burdens? An injustice occurs, the report states, when some benefit to which a person is entitled is denied without good reason, or when some burden is imposed unduly.

The historical context here is direct and deliberate. The Belmont Report explicitly names the exploitation of ward patients, of prisoners in Nazi concentration camps, and of disadvantaged rural Black men in the Tuskegee study as examples of the injustice it was designed to prevent. The pattern in each case was the same: vulnerable or easily available populations bore the burdens of research, while the benefits flowed primarily to those who were not asked to bear those burdens.

The principle of justice in the modern research context has two directions, and CRCs work at the intersection of both. On the protective side, it means that selection of participants must be justified by scientific criteria relevant to the research question, not by the convenience of a particular population's availability, or their social position, or their inability to refuse. On the access side, it means that groups likely to benefit from a treatment should not be systematically excluded from the research that produces evidence about it. This is why the FDA actively promotes diverse clinical trial enrollment, and why the Common Rule includes requirements for equitable selection of subjects.

The Belmont Report also applies justice to the distribution of research benefits: whenever research supported by public funds leads to the development of therapeutic procedures, justice demands both that those procedures not provide advantages only to those who can afford them, and that the research not unduly involve persons from groups unlikely to benefit from its applications. This principle underlies much of the policy debate about clinical trial diversity and equitable access to treatments — debates that are still very much active today.

How the Three Principles Map to Research Practice

The Belmont Report is explicit that the three principles are not abstract ideals. They have direct practical applications. Each principle maps to a specific area of research practice:

• Respect for persons → Informed consent. The entire informed consent framework, the required elements, the ongoing process, the re-consent obligations, the special protections for vulnerable populations — flows directly from this principle.
• Beneficence → Risk/benefit assessment. IRB review of protocols, the investigator's ongoing safety monitoring obligations, adverse event reporting, and the sponsor's authority to modify or halt a study all exist to maintain a defensible risk/benefit balance throughout the trial.
• Justice → Selection of subjects. Inclusion and exclusion criteria must be scientifically justified. Participant selection must not systematically impose burdens on those least able to bear them or exclude those most likely to benefit from the research.

From Principles to Regulations: The Common Rule

The Belmont Report's influence on U.S. federal regulations was direct and immediate. As HHS's overview of the Common Rule states, the current U.S. system of protection for human research subjects is heavily influenced by the Belmont Report. In 1981, using the report as foundational background, HHS and the FDA revised their existing human subjects regulations to make them as compatible as possible. The Federal Policy for the Protection of Human Subjects, the Common Rule, was published in 1991 and codified in separate regulations by 15 federal departments and agencies.

The HHS regulations at 45 CFR Part 46 include four subparts: subpart A (the Common Rule itself, covering basic protections), subpart B (additional protections for pregnant women, human fetuses, and neonates), subpart C (additional protections for prisoners), and subpart D (additional protections for children). Each of the additional subparts reflects the Belmont Report's principle of protecting those with diminished autonomy — recognizing specific populations whose circumstances limit the freedom and voluntariness of their participation in research.

The Common Rule was most recently revised in 2017 and 2018, with a compliance date of January 21, 2019. The revised rule updated provisions on informed consent, IRB review, and research involving biospecimens and identifiable private information, while retaining the Belmont Report's three principles as its ethical foundation. The revised rule explicitly states that alternative procedures for waiving requirements must be consistent with the principles of the Belmont Report — codifying its ongoing authority in federal regulation.

The FDA's parallel regulations at 21 CFR Part 50 and 21 CFR Part 56 govern FDA-regulated research. The FDA is not a Common Rule agency because its statutory authority differs from HHS's, but its human subjects protections are built on the same Belmont foundations. For most clinical trials involving FDA-regulated products that are also federally funded, both sets of regulations apply simultaneously, and both trace back to the same 1979 document.

The Belmont Report in 2026: Still the Foundation

More than four decades after its publication, the Belmont Report remains the foundational ethical document of clinical research in the United States. Its three principles have been incorporated not only into federal regulations but into the international framework for clinical research. The Declaration of Helsinki, most recently revised in October 2024, reflects the same core principles, as does the ICH E6(R3) GCP guideline finalized in January 2025, which explicitly grounds its requirements in the ethical principles established by the Declaration of Helsinki, and by extension, the same framework the Belmont Report articulates for U.S. research.

The questions the report raised have not been fully resolved, and the report's authors did not expect them to be. They created an analytical framework, not a rulebook. Current debates about consent for genomic research, the ethics of post-trial access to beneficial treatments, the representation of diverse populations in clinical trials, and the appropriate use of AI in research data generation are all being worked through using the principles of respect for persons, beneficence, and justice as the framework for reasoning.

For CRCs, understanding the Belmont Report means understanding that the work of research ethics is ongoing, that the principles provide not a list of rules to follow, but a way of asking the right questions. When you review a consent form and wonder whether a participant truly understood what they agreed to, you are applying respect for persons. When you report an adverse event that might shift the study's risk/benefit balance, you are applying beneficence. When you notice that your site's recruitment materials systematically exclude a population who should have access to the trial, you are applying justice. The framework is 46 years old. The questions it was designed to help answer are as current as tomorrow's protocol.

The National Research Act: 50 Years Later

July 12, 2024 marked the 50th anniversary of the signing of the National Research Act (Public Law 93-348), the law that directly created the National Commission and set the process in motion that produced the Belmont Report. The HHS OHRP 50th Anniversary commemorative materials describe the Act as a response to public outcry over the Tuskegee study — federal action triggered by 40 years of documented ethical failure on American soil. The anniversary serves as a reminder of how recently these protections were established, and what their absence cost.

The HHS OHRP FAQ on 45 CFR Part 46 documents that in 1991, more than a decade after the Belmont Report, 14 other Federal departments and agencies joined HHS in adopting a uniform set of rules based on the Belmont principles, creating the Common Rule. The slow, incremental spread of these protections across the federal government is a reminder that institutional ethics does not change overnight. It changes under sustained pressure, through legislation, through landmark reports, and through the ongoing work of the people, IRB members, investigators, and CRCs, who apply principles to specific situations every day.

The Belmont Report on Certification Exams

For CRCs preparing for the CCRC (ACRP) or CCRP (SOCRA) certification exams, the Belmont Report is foundational material. Both organizations publish an official Exam Content Outline (sometimes called a Detailed Content Outline or DCO) that describes the knowledge domains covered. We recommend checking the current outline directly from ACRP and SOCRA before building your study plan, since content outlines are updated periodically.

What we can say is that understanding the three principles at the conceptual level described in this guide, including how each one connects to specific regulatory requirements and real historical events, builds the kind of working knowledge that holds up under applied questions. Reading the Belmont Report itself is more valuable than any summary, including this one. It is short, readable, and freely available. The Acronyms & Flashcards section of this site includes Belmont Report terms for general review.